ERAS Erasca, Inc.
FY2025 10-K
Erasca, Inc. (ERAS) filed its fiscal year 2025 10-K annual report with the SEC on Mar 12, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Precision oncology company focused exclusively on discovering and developing therapies targeting RAS/MAPK pathway-driven cancers
- • New emphasis: Clinical-stage programs ERAS-0015 (pan-RAS molecular glue) and ERAS-4001 (pan-KRAS inhibitor) initiated INDs May 2025, first clinical data expected H1/H2 2026
Management Discussion & Analysis
- • No revenue generated; net loss $124.5M in 2025 vs $161.7M in 2024, improving by $37.1M
- • Operating expenses down to $140.9M in 2025 from $179.6M in 2024; R&D expense 22% lower at $92.9M vs $115.4M
Risk Factors
- • Regulatory risk from compliance with EU Clinical Trials Regulation (CTR) effective January 31, 2025 impacting multi-center trial approvals
- • Geopolitical risk from potential delays and cost increases due to evolving U.S. tariff and import/export regulations affecting operations
Financial SummaryXBRL
Net Income
-$125M
ROE
-38.3%
Total Assets
$396M
EPS (Diluted)
$-0.44
Operating Cash Flow
-$95M
Source: XBRL data from Erasca, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Erasca, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.